Fungicidal effect of three new synthetic cationic peptides against Candida albicans

Oral Diseases

Volumn 10, Issue 4, 2004, Pages 221-228

  Nikawa, H ^a   Fakashima, H ^a   Makihira, S ^a   Hamada, T ^a   Samaranayake, L P ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antifungal activity; Candida albicans; Cationic peptide

Indexed keywords

ANTIFUNGAL AGENT; HISTATIN 5; JH 8194; JH 8195; JH 8944; LACTOFERRIN; LACTOFERRIN B; LACTOFERRIN B[17-30]; PEPTIDE DHVAR 4; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO ACID SEQUENCE; ARTICLE; CANDIDA ALBICANS; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DILUTION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ERYTHROCYTE; FUNGAL CELL; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; HEMOLYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CANDIDA ALBICANS; CIRCULAR DICHROISM; COLONY COUNT, MICROBIAL; FEMALE; HEMOLYSIS; HUMANS; ISOELECTRIC POINT; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, SECONDARY;

EID: 3042755651     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2004.01010.x     Document Type: Article

References (30)

1. Bellamy W, Wakabayashi H, Takase M, Kawase K, Shimamura S, Tomita M (1993). Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med Microbiol Immunol 182: 97-105.
2. Dathe M, Wieprecht T, Nikolenko H et al (1997). Hydrophobicity, hydrophobic moment and angle subtended by charged residues modulate antibacterial and haemolytic activity of amphipathic helical peptides. FEBS Lett 403: 208-212.
3. Edgerton M, Koshlukova SE, Lo TE, Chrzan BG, Straubinger RM, Raj PA (1998). Candidacidal activity of salivary histatins. Identification of a histatin 5-binding protein on Candida albicans. J Biol Chem 273: 20438-20447.
4. Helmerhorst EJ, Reijnders IM, van't Hof W, Veerman EC, Nieuw Amerongen AV (1999a). A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides. FEBS Lett 449: 105-110.
5. Helmerhorst EJ, Reijnders IM, van't Hof W, Simoons-Smit I, Veerman EC, Amerongen AV (1999b). Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob Agents Chemother 43: 702-704.
6. Jones EM, Smart A, Bloomberg G, Burgess L, Millar MR (1992). Lactoferricin, a new antimicrobial peptide. J Appi Bacteriol 77: 208-214.
7. Lupetti A, Paulusma-Annema A, Welling MM, Senesi S, van Dissel JT, Nibbering PH (2000). Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother 44: 3257-3263.
8. Murakami Y, Nagata H, Shizukuishi S et al (1994). Histatin as a synergistic stimulator with epidermal growth factor of rabbit chondrocyte proliferation. Biochem Biophys Res Commun 198: 274-280.
9. Nikawa H, Hayashi S, Nikawa Y, Hamada T, Samaranayake LP (1993a). Interactions between denture lining material, protein pellicles and Candida albicans. Arch Oral Biol 38: 631-634.
10. Nikawa H, Samaranayake LP, Tenovuo J, Pang KM, Hamada T (1993b). The fungicidal effect of human lactoferrin on Candida albicans and Candida krusei. Arch Oral Biol 38: 1057-1063.
11. Nikawa H, Samaranayake LP, Tenovuo J, Hamada T (1994). The effect of antifungal agents on the in vitro susceptibility of Candida albicans to apo-lactoferrin. Arch Oral Biol 39: 921-923.
12. Nikawa H, Samaranayake LP, Hamada T (1995). Modulation of the anti-Candida activity of apo-lactoferrin by dietary sucrose and tunicamycin in vitro. Arch Oral Biol 40: 581-584.
13. Nikawa H, Nishimura H, Yamamoto T, Hamada T, Samaranayake LP (1996). The role of salivary or serum pellicle in the colonization process of Candida albicans on denture acrylic in vitro. Microbial Ecol Health Dis 9: 35-48.
14. Nikawa H, Jin C, Makihira S, Hamada T, Samaranayake LP (2002). Susceptibility of Candida albicans isolates from the oral cavities of HIV-positive patients to histatin-5. J Prosthet Dent 88: 263-267.
15. Oppenheim FG, Xu T, McMillian FM et al (1988). Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem 263: 7472-7477.
16. Perczel A, Park K, Fasman GD (1992). Analysis of the circular dichroism spectrum of proteins using the convex constraint algorithm: a practical guide. Anal Biochem 203: 83-93.
17. Pollock JJ, Denepitiya L, MacKay BJ, Iacono VJ (1984). Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans. Infect Immun 44: 702-707.
18. Raj PA, Edgerton M, Levine MJ (1990). Salivary histatin 5: dependence of sequence, chain length, and helical conformation for candidacidal activity. J Biol Chem 265: 3898-3905.
19. Samaranayake LP (2002). Essential microbiology for dentistry, 2nd edn. Churchill Livingstone: Edinburgh, UK.
20. Samaranayake LP, Holmstrup P (1989). Oral candidiasis and the human immunodeficiency virus infection. J Oral Pathol Med 18: 554-564.
21. Samaranayake LP, MacFarlane TW, Lamey PJ, Ferguson MM (1986). A comparison of oral rinse and imprint sampling techniques for the detection of yeast, coliform and Staphylococcus aureus carriage in the oral cavity. J Oral Pathol 15: 251-254.
22. Samaranayake LP, Cheung LK, Samaranayake YH (2002). Candidiasis and other fungal diseases of the mouth. Dermatol Ther 15: 252-270.
23. Shai Y (1999) Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1462: 55-70.
24. Silverman S Jr, Migliorati CA, Epstein JB, Samaranayake LP (1990). Laboratory diagnosis of oral candidosis. In: Samaranayake LP, MacFarlane TW, eds. Oral candidosis. Butterworth & Co. Ltd: London, pp. 213-237.
25. Situ H, Bobek LA (2000). In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrob Agents Chemother 44: 1485-1493.
26. Stemberg S (1994). The emerging fungal threat. Science 266: 1632-1634.
27. Tobgi RS, Samaranayake LP, MacFarlane TW (1987). The in vitro susceptibility of Candida species to lysozyme. Oral Microbiol Immunol 3: 35-39.
28. Tsai H, Bobek LA (1997). Human salivary histatin-5 exerts potent fungicidal activity against Cryptococcus neoformans. Biochim Biophys Acta 1336: 367-369.
29. Wakabayashi H, Abe S, Teraguchi S, Hayasawa H, Yamaguchi H (1998). Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob Agents Chemother 42: 1587-1591.
30. White TC, Marr KA, Bowden RA (1998). Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11: 382-402.